Omnitrope approval raises concerns in biotech industry

The FDA's recent approval of a generic version of Pfizer's biotech drug Genotropin has raised concerns in the industry about a possible change in approval of copies of biotech drugs. The biotech industry has long argued its products are too complex to be copied safely, and Congress and the FDA hesitated allowing copies; but the generics industry is pushing for a more flexible policy.

View Full Article in:

San Jose Mercury News (Calif.) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY